Recently, Kexing Biopharm and Haichang Biotech held an investment cooperation signing ceremony in Shenzhen. Guests from the China Pharmaceutical Innovation Promotion Association, SDIC Venture Capital, and Songshan Lake Science City Group attended the signing ceremony.
Deepen Cooperation, Create the Future TogetherAt the ceremony, Kexing Biopharm and Haichang Biotech announced that they would further deepen their cooperation and establish a strategic partnership. Kexing Biopharm enjoys an excellent reputation in both Chinese and international markets due to its strong R&D capabilities, large-scale production capacity, and outstanding overseas commercialization strength. Meanwhile, Haichang Biotech has accumulated extensive experience in drug development, delivery system innovation, and industrialization. The products co-developed by the two parties have been successfully approved in 34 countries worldwide, rapidly advancing their international expansion.Kexing Biopharm Chairman Deng Xueqin stated: "The successful experience from our initial collaboration, along with the strategic synergy and complementary strengths between us, has driven us to further deepen our cooperation, laying a solid foundation for the long-term development of both parties in the future."Zhao Xiaobin, Chairman of Haichang Biotech, stated: "Haichang Biotech will continue to focus on innovative research and development to provide more high-quality products for patients worldwide. We look forward to joining hands with Kexing Biopharm to explore more commercial cooperation opportunities in the biopharmaceutical field, driven by technological innovation and an international commercial layout targeting Europe and America, thereby promoting the continuous development of the industry."Embracing All Rivers, Sharing the Same Vision for the FutureThe signing ceremony, themed "Embracing Diversity · United for a Shared Future," symbolizes the beautiful vision of openness, inclusiveness, and joint progress between both parties. Representatives from both sides, Zhao Yanqing, General Manager of Kexing Biopharm, and Zhou Xiaoli, Vice President of Haichang Biotech, signed the investment cooperation agreement at the ceremony.Song Ruilin, Executive President of the China Pharmaceutical Innovation and Research Development Association, Ye Zhenhui, Chairman of Songshan Lake Science City, and Lin Shuang, General Manager,Zhang Yibo, Investment Director of SDIC Venture CapitalThe attending guests, including [names], delivered speeches on this cooperation, expressing full confidence in the deep strategic partnership between Kexing Biopharm and Haichang Biotech. Through equity cooperation, both parties aim to further strengthen the development and commercialization of their future products in the U.S. and European markets.This signing ceremony is not only a deep affirmation of the past cooperation between the two parties, but also a promising outlook for future collaboration. Haichang Biotech and Kexing Biopharm will jointly open a new chapter in the biopharmaceutical field, promote technological innovation and the continuous development of the industry, and bring more health benefits to patients worldwide.About Kexing Biopharm 
Kexing Biopharm Co., Ltd. (Abbreviation: Kexing Biopharm, Stock Code: 688136) is an innovative international biopharmaceutical company mainly engaged in the R&D, production, and sales of recombinant protein drugs and microecological preparations. Focusing on treatment areas such as antiviral, oncology and immunology, hematology, gastroenterology, and degenerative diseases, the company has built cutting-edge biotechnology platforms for novel proteins, novel antibodies, and nucleic acid drugs. It adheres to a platform-based development model driven by "innovation and internationalization," while exploring the wide application of biotechnology in the healthcare sector, actively nurturing and incubating new industries, and striving to become a leader in high-quality biopharmaceuticals to serve patients worldwide. The company's core products rank among the top in their respective categories in China, covering approximately 22,700 terminals across provinces and regions in China, including over 7,500 tiered hospitals. It has gained market access in nearly 70 countries around the world, including Brazil, the Philippines, and Indonesia, and has achieved sales.
About Haichang Biotech 
Haichang Biotech, located in China Medical Valley, Hangzhou, is a national-level specialized and innovative "little giant" enterprise that integrates the research, production, and sales of pharmaceuticals, with a primary focus on the technological innovation and development of biopharmaceuticals. The company adheres to its core values of "sharing, progress, truth-seeking, and pragmatism," centering on the development and industrialization of drug delivery systems. It specializes in the development of nucleic acid innovative drugs such as small nucleic acid drugs, mRNA vaccines, and complex injectables. Currently, injectable paclitaxel (albumin-bound) has been approved in 34 countries including China, the UK, and the EU, with registration applications ongoing in multiple countries along the Belt and Road; small nucleic acid 1...The new drug HC0301 has received dual approval from the FDA and NMPA and is currently undergoing a global multi-center Phase II clinical trial; the mRNA COVID-19 vaccine booster has been approved by the FDA for clinical trials, marking the first mRNA vaccine product in China to receive U.S. clinical approval. The product pipeline covers areas such as anti-tumor, tumor immunotherapy, pain relief, and infectious disease prevention.
